FindMyRecallSubscribe
Class II: temporary or reversible health riskOngoing

ProRx Semaglutide Injection Recall

Semaglutide Injection, 12

ProRx LLC · Exton, PA

Risk level
Class II
Reported by FDA
Nov 5, 2025
Recall ID
D-0114-2026
Check your lot numberHow we source this data

Summary

ProRx recalled Semaglutide Injection starting Oct 15, 2025. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0114-2026 on Nov 5, 2025. Reason: Lack of Assurance of Sterility. Status: Ongoing.

Why it was recalled

Lack of Assurance of Sterility

Product description

Semaglutide Injection, 12.5/5mL (2.5 mg/mL), 5mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-225-09

Lot numbers, UPCs & expiration codes

Lot# Prorx04282025-3

Where it was sold

TX and UT

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0114-2026
Classification
Class II
Status
Ongoing
Recall initiated
Oct 15, 2025
FDA report date
Nov 5, 2025
Quantity
2,809 vials
Recall type
Voluntary: Firm initiated
Recalling firm
ProRx LLC

Original FDA data

Every field from FDA enforcement report D-0114-2026, exactly as published.

Show all FDA fields
City
Exton
State
PA
Status
Ongoing
Country
United States
Event ID
97808
Address
619 Jeffers Cir
Code information
Lot# Prorx04282025-3
Postal code
19341-2540
Report date
Nov 5, 2025
Product type
Drugs
Recall number
D-0114-2026
Classification
Class II
Recalling firm
ProRx LLC
Product quantity
2,809 vials
Reason for recall
Lack of Assurance of Sterility
Voluntary / mandated
Voluntary: Firm initiated
Product description
Semaglutide Injection, 12.5/5mL (2.5 mg/mL), 5mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-225-09
Distribution pattern
TX and UT
Recall initiation date
Oct 15, 2025
Initial firm notification
Letter
Center classification date
Oct 27, 2025

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0114-2026, published Nov 5, 2025. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls